Introduction
Methods
Data sources and search strategy
Inclusion and exclusion criteria
Design
Participants
Intervention and comparison
Outcomes
Timing
Study selection and data extraction
Quality assessment
Methodological quality assessment
Evidence quality assessment of outcomes
Data synthesis and analysis
X-axis: effect estimate
Y-axis: literature size estimate
Bubble size: numbers of included SRs
Color: evidence quality of the findings
Results
Literature selection
Characteristics of included SRs
Annual trends in publications
Geographical distribution
Primary studies and participants
First author, publication year | Disease | Design of primary studies | No. of primary studies | No. of included RCTs | No. of participants | Outcome | Conclusion |
---|---|---|---|---|---|---|---|
Munshi 2019 [31] | ARDS | RCT, observational study | 5 | 2 | 899 | 60-Day mortality, treatment failure, mortality at longest available follow-up | Probably beneficial |
Shrestha 2022 [38] | Dependent ARDS | RCT, retrospective study, prospective observational study, cohort study | 12 | 2 | 1208 | 30-Day mortality, 90-day mortality, in-hospital mortality, ICU mortality, length of hospital stays, average ICU length of stay | Inconclusive |
Tillmann 2017 [27] | Severe ARDS | RCT, cohort study | 26 | 1 | 1674 | Survival, adverse events | Inconclusive |
Mendes Pedro Vitale, 2019 [30] | Severe ARDS | RCT | 2 | 2 | 429 | Mortality, treatment failure, need for renal replacement therapy, ICU lengths of stay, hospital lengths of stay | Probably beneficial |
Alain Combes, 2020 [32] | Severe ARDS | RCT | 2 | 2 | 429 | 90-Day mortality, 90-day treatment failure, 28-day mortality, 60-day mortality, ICU-free days, hospital-free days, ventilation-free days, vasopressor-free days, RRT-free days, neurological failure-free days | Beneficial |
Zhu, 2021 [36] | Severe ARDS | RCT, retrospective or prospective cohort study | 7 | 2 | 867 | 90-Day mortality, 30-day mortality, 60-day mortality, hospital mortality, mortality at the longest duration of follow-up, device-related adverse events (pneumothorax, massive bleeding, intracranial bleeding, cardiac arrest, massive stroke and death due to MV or ECMO) | Beneficial |
Munshi, 2014 [24] | ARF | RCT, observational study | 10 | 4 | 1248 | In-hospital mortality, ICU length of stay, adverse events (bleeding, barotrauma, and sepsis) | Inconclusive |
Mitchell, 2010 [22] | ARF due to H1N1 influenza pandemic | RCT, cohort study | 6 | 3 | 827 | Mortality | Inconclusive |
Alberto Zangrillo, 2013 [23] | ALI due to H1N1 influenza infection | Observational study | 8 | 0 | 1357 | Mortality | Beneficial |
Alshamsi Fayez, 2020 [34] | ALF or ACLF | RCT | 25 | 25 | 1796 | Mortality, hepatic encephalopathy outcome, adverse events (hypotension, bleeding, thrombocytopenia, line infections) | Probably beneficial |
Ouweneel Dagmar, 2016 [26] | Cardiac arrest | Cohort study | 10 | 0 | 3127 | 30-Day survival rate, 30-day favorable neurological outcome | Beneficial |
Beyea, 2018 [28] | Cardiac arrest | Case series, cohort study | 75 | 0 | 5570 | Neurologic status at hospital discharge, survival | Inconclusive |
Twohig, 2019 [29] | Cardiac arrest | Retrospective or prospective observational study | 9 | 0 | 26,030 | Survival at hospital discharge or 30 days, neurological function | Probably beneficial |
Miraglia, 2020 [33] | Cardiac arrest | Cohort study | 6 | 0 | 1108 | 30-Day and long-term favorable neurological outcome, 30-day and long-term survival | Probably beneficial |
Miraglia, 2020 [35] | Cardiac arrest | Cohort study, case–control study | 6 | 0 | 1750 | Long-term neurological intact survival | Probably beneficial |
Scquizzato, 2022 [37] | Cardiac arrest | RCT, observational study | 6 | 2 | 1177 | Survival with favorable neurological outcome at the longest follow-up available, survival at the longest follow-up available/hospital discharge/30 days, rate of neurological impairments | Beneficial |
Ahn Chiwon, 2016 [25] | Cardiac arrest of cardiac origin | Retrospective or prospective cohort study | 11 | 0 | 38,160 | Survival, overall neurologic outcome | Probably beneficial |
First author, publication year | Inclusion criteria | Exclusion criteria | Method of quality appraisal or risk of bias |
---|---|---|---|
Munshi, 2019 [31] | ① RCT and observational study; ② Refractory hypoxia in adults with ARDS (including treatments such as inhaled nitric oxide or highfrequency oscillation); ③ MV plus venovenous (VV) ECMO compared with conventional MV; ④ Reported mortality at any time | Main focused venoarterial (VA) ECMO studies | The cochrane riskofbias (ROB) tool and NewcastleOttawa Scale (NOS) |
Shrestha, 2022 [38] | ① Prospective as well as retrospective observational studies and randomized clinical trials; ② Published after 2000; ③ ARDS patients > 18 years of age; ④ Interventions included ECMO (VV/VA or veno arteriovenous (VAV) compared with conventional treatment of MV or other adjunctive therapies; ⑤ Outcomes involving the mortality rate, clinical improvement and recovery, length of hospital stay, adverse effects of ECMO, mean difference of clinical improvement, and healing | ① Comments, editorials, viewpoint articles, systematic reviews, or meta-analyses; ② Non-ARDS patients, less than 18 years of age, or pregnant patients; ③ ECMO used for the management of cases other than ARDS; ④ Not mentioned our outcome of interest | The Cochrane ROB 2.0 tool and the Joanna Briggs Institute (JBI) quality assessment tools |
Tillmann, 2017 [27] | ① Patients > 16 years with severe ARDS as per the Berlin criteria, or classified as having ARDS as per the 1994 American-European Consensus Conference Definition with a PaO2:FiO2 ratio < 100; ② Intervention group received ECMO; ③ Treatment with low tidal volume MV of 8 cm3/kg or less; ④ Reported survival to hospital or ICU discharge | Used ECMO as a pre-specified bridge to lung transplantation | NOS |
Mendes Pedro Vitale, 2019 [30] | ① RCT; ② Adult patients with ARDS; ③ Used ECMO support plus protective MV compared with protective MV alone | Neonatal, pediatric, and experimental data, as well as case series, observational trials and case reports | The Cochrane ROB tool |
Alain Combes, 2020 [32] | ① RCT; ② Published after 2000; ③ Patients with ARDS fulfilling the American-European Consensus Conference definition or the Berlin definition for ARDS; ④ VV ECMO in the experimental group and conventional ventilatory management in the control group | Not mentioned | The Cochrane ROB tool |
Zhu, 2021 [36] | ① Randomized and observational studies; ② Adult populations (age ≥ 18 years old); ③ Comparing ECMO therapy with MV alone in the treatment of severe ARDS; ④ Reported mortality outcomes | ① Animal studies or case reports; ② lacked
a comparison group; ③ included patients <
18 years | Modified Jadad scores, the Cochrane ROB tool, or NOS |
Munshi, 2014 [24] | ① ARF patients older than 1 month of age; ② Received ECLS; ③ Compared with patients receiving MV; ④ Reported mortality as an outcome | Not mentioned | The Cochrane ROB tool |
Mitchell, 2010 [22] | ① Controlled trials or cohort studies; ② Reported on the use of ECMO in
influenza patients; ③ Included a minimum of 10 patients in each group; ④
Reported comparisons between patients with ARF managed with and without
ECMO; ⑤ Reported mortality rates | Neonatal and pediatric studies (patients under 18 years of age) | A nine-point scale combining elements from Jadad’s and Chalmers’ scales |
Alberto Zangrillo, 2013 [23] | ① Reported on 10 or more patients; ② With confirmed or suspected H1N1 influenza infection; ③ Receiving ECMO | ① Reported on fewer than 10 patients treated with ECMO; ② Duplicate publication | NOS |
Alshamsi Fayez, 2020 [34] | ① RCT; ② Adults with ALF or ACLF; ③ Intervention with any form of artificial or bio-artificial ECLS; ④ Control group received supportive care not including ECLS; ⑤ All-cause mortality or liver-related mortality, bridging to liver transplant, improvement of HE and adverse events such as hypotension, bleeding, thrombocytopenia, line infection, and citrate toxicity as outcomes | Not mentioned | The Cochrane ROB tool |
Ouweneel Dagmar, 2016 [26] | ① Diagnosed with either refractory in-hospital or out-of-hospital cardiac arrest
or cardiogenic shock after AMI; ② Patients with ECLS support and a control
group without ECLS support | ① Case reports, non-human studies, pediatric studies, and reviews; ② not reported on survival to discharge, 30-day outcome or 6-month outcome | A modified version of NOS |
Beyea, 2018 [28] | ① Documented OHCA in adults (age ≥ 16 years); ② Used “ECPR” or
equivalent search term, as the intervention; ③ Had either CCPR, defined as
either basic life support or advanced cardiovascular life support protocols, or
no comparator; ④ Reported hospital outcomes | ① Under age 16 years; ② Cardiac arrests of traumatic etiology, or patients suffered in-hospital cardiac arrest including in the emergency department | NOS |
Twohig, 2019 [29] | ① Observational studies; ② Human adult participants (≥ 17 years old); ③ VA
ECMO initiated during cardiac arrest (ECPR); ④ Minimal data outcome of 30-day/hospital mortality reported
| ① Languages other than English; ② Traumatic cardiac arrest; ③ Comparator not CCPR (only for ECPR vs. CCPR papers); ④ Minimal data outcome not reported or reported at other later time intervals | The Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool |
Miraglia, 2020 [33] | ① Published in English as full-text articles in indexed journals; ② Used propensity score-matched analysis as part of the study design; ③ Adult participants (≥ 18 years old); ④ Resuscitated from in- and out-of-hospital cardiac arrest; ⑤ Received ECPR; ⑥ Reported neurological outcomes | ① Review articles, opinions, letters, case reports, case series, meta-analyses, and studies reported insufficient data; ② Conducted on pregnancy, pediatric populations, presumed pregnancy, or patients with a pulse (eg, cardiogenic shock) | NOS |
Miraglia, 2020 [35] | ① Employing patient-level randomization or cluster randomization comparing ECPR vs. no ECPR and/or conventional CPR; ② Adults suffering in- or out-of- hospital cardiac arrest, with resuscitation attempted by a bystander or healthcare provider; ③ Compared ECMO using pump-driven VA circuits vs. no ECPR and/or conventional CPR; ④ Long-term neurologically intact survival after in- and out-of- hospital cardiac arrest as the primary outcomes of interest | ① Considering in- or out-of- hospital cardiac arrest in pediatrics and pregnancy; ② considering in- or out-of- hospital cardiac arrest due to trauma, hypothermia, and toxic substances, as the core interventions provided by healthcare providers (CPR and early defibrillation) | ROBINS-I tool |
Scquizzato, 2022 [37] | ① Randomized trials and observational studies reporting propensity score-matched data; ② Comparing adult out-of- hospital cardiac arrest patients treated with ECPR with patients treated with CCPR (i.e., basic and advanced life-support maneuvers) | ① Feasibility studies; ② Enrolling less than 20 patients; ③ Not reporting the primary outcome of survival with favorable neurological outcome | The Cochrane ROB 2.0 tool |
Ahn Chiwon, 2016 [25] | ① Adult patients of cardiac-origin arrest (age 18–75 years); ② Does cardiopulmonary resuscitation with ECMO; ③ Compared to conventional cardiopulmonary resuscitation; ④ Survival rate and neurological outcome as outcomes | ① Comments, reviews, case reports, editorials, letters, conference abstracts, meta-analyses, or animal studies; ② Languages other than English; ③ Duplicate studies; ④ Irrelevant populations; ⑤ Inappropriate controls | The Cochrane ROB tool |
Methodological quality of included SRs
Evidence quality of included SRs
Study | Design | Risk of bias | Consistency | Directness | Imprecision | Reporting bias | Strength | Gradient | Confounding | Overall confidence |
---|---|---|---|---|---|---|---|---|---|---|
Munshi, 2019 [31] | RCT, observational study | 0 | 0 | 0 | 0 | 0 | 0 | + 1 | 0 | ⨁⨁⨁◯ moderate |
Shrestha, 2022 [38] | RCT, retrospective study, prospective observational study, cohort study | 0 | − 1 | 0 | 0 | 0 | 0 | 0 | 0 | ⨁◯◯◯ very low |
Tillmann, 2017 [27] | RCT, cohort study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ⨁⨁◯◯ low |
Mendes Pedro Vitale, 2019 [30] | RCT | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | ⨁⨁⨁◯ moderate |
Alain Combes, 2020 [32] | RCT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ⨁⨁⨁⨁ high |
Zhu, 2021 [36] | RCT, retrospective or prospective cohort study | 0 | 0 | 0 | 0 | 0 | + 1 | 0 | 0 | ⨁⨁⨁◯ moderate |
Munshi, 2014 [24] | RCT, observational study | 0 | − 1 | 0 | − 1 | 0 | 0 | 0 | 0 | ⨁◯◯◯ very low |
Mitchell, 2010 [22] | RCT, cohort study | − 1 | − 1 | 0 | − 1 | 0 | 0 | 0 | 0 | ⨁◯◯◯ very low |
Alberto Zangrillo, 2013 [23] | Observational study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ⨁⨁◯◯ low |
Alshamsi Fayez, 2020 [34] | RCT | 0 | 0 | 0 | − 1 | 0 | 0 | 0 | 0 | ⨁⨁⨁◯ moderate |
Ouweneel Dagmar, 2016 [26] | Cohort study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ⨁⨁◯◯ low |
Beyea, 2018 [28] | Case series, cohort study | − 1 | − 1 | 0 | 0 | 0 | + 1 | 0 | 0 | ⨁◯◯◯ very low |
Twohig, 2019 [29] | Retrospective or prospective observational study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ⨁⨁◯◯ low |
Miraglia, 2020 [33] | Cohort study | 0 | 0 | 0 | 0 | 0 | + 1 | 0 | 0 | ⨁⨁⨁◯ moderate |
Miraglia, 2020 [35] | Cohort study, case–control study | 0 | 0 | 0 | − 1 | 0 | 0 | 0 | 0 | ⨁◯◯◯ very low |
Scquizzato, 2022 [37] | RCT, observational study | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ⨁⨁◯◯ low |
Ahn Chiwon, 2016 [25] | Retrospective or prospective cohort study | 0 | − 1 | 0 | − 1 | 0 | + 1 | 0 | 0 | ⨁◯◯◯ very low |